Marc Duey - 23 Aug 2023 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ John Hamill, as Attorney-in-Fact
Issuer symbol
APRE
Transactions as of
23 Aug 2023
Net transactions value
$0
Form type
4
Filing time
24 Aug 2023, 21:50:02 UTC
Previous filing
01 Aug 2022
Next filing
21 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Conversion of derivative security $0 +4,009,690 +2539% $0.000000 4,167,589 23 Aug 2022 Direct
transaction APRE Common Stock Award $0 +500 +0.24% $0.000000 208,878 23 Aug 2023 Direct F1, F2
transaction APRE Common Stock Conversion of derivative security $0 +11,610 $0.000000 602 23 Aug 2022 By Spouse F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Series A Non-Voting Convertible Preferred Stock Conversion of derivative security $0 -400,969 -100% $0.000000* 0 23 Aug 2022 Common Stock 4,009,690 $0.000000 Direct F4
transaction APRE Series A Non-Voting Convertible Preferred Stock Conversion of derivative security $0 -1,161 -100% $0.000000* 0 23 Aug 2022 Common Stock 11,610 $0.000000 By Spouse F3, F4
transaction APRE Stock Options (Right to Buy) Award $0 +2,000 $0.000000 2,000 23 Aug 2023 Common Stock 2,000 $3.65 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2 Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023
F3 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
F4 Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock ("Common Stock") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date.
F5 The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Remarks:

Exhibit 24 - Power of Attorney